Intabio, Inc. and Protein Metrics Inc., developers of advanced analytical tools for accelerating biopharmaceutical development and manufacturing, today announced a co-development and co-marketing agreement to couple Intabio’s Blaze™ instrument system with the Byos® software suite from Protein Metrics
| NEWARK, Calif. and CUPERTINO, Calif., March 11, 2020 /PRNewswire/ -- Intabio, Inc. and Protein Metrics Inc., developers of advanced analytical tools for accelerating biopharmaceutical development and manufacturing, today announced a co-development and co-marketing agreement to couple Intabio’s Blaze™ instrument system with the Byos® software suite from Protein Metrics. The integrated Blaze-Byos platform will address a critical bottleneck for biopharmaceutical developers by automating analysis of large protein structure/quality data sets to confirm product consistency and quality.
With Intabio’s Blaze system, drug developers can monitor multiple Critical Quality Attributes (CQAs) directly on intact biotherapeutic proteins. The system couples two gold-standard analytical techniques - imaged capillary isoelectric focusing (iCIEF) and high-resolution mass spectrometry (HRMS) - into a single 15-minute assay with a hundred times the throughput of legacy approaches. Protein Metrics’ Byos Platform allows researchers to move from raw data files to report in just minutes, with the click of a mouse. Designed to support users with a range of expertise Protein Metrics software is installed in over 100 biopharmaceutical companies worldwide. By launching best-in-class protein analysis workflows, Byos significantly improves laboratory efficiency, reproducibility, and reporting across the development pipeline. “The Blaze system eliminates a serious bottleneck created by traditional, cumbersome laboratory approaches to identifying and characterizing CQAs, while the Byos platform dramatically boosts the speed of MS data analysis,” said Intabio’s CEO and co-founder, Lena Wu, Ph.D. “The Blaze-Byos combination will enable critical drug development decisions to be made months earlier.” “For organizations that traditionally rely on cIEF measurements, the combination of Byos workflows with the Blaze platform offers a rapid, vendor-neutral means to provide detailed mass spec analysis of sample heterogeneity and comparability,” said Eric Carlson, President & CEO of Protein Metrics. About Intabio Intabio, Inc. is a Silicon Valley-based company developing analytical solutions to transform biotherapeutic development and manufacturing with products that provide early product quality characterization and profound efficiency gains across all stages of biopharmaceutical development and manufacturing. Intabio’s first product, the Blaze system, is a microchip-based instrument system that provides rapid detection and identification of subtle protein modifications - modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins. For more information, visit http://www.intabio.com. About Protein Metrics Protein analysis should never be limited by software. With a clear focus on protein characterization, Protein Metrics’ vendor-neutral software allows scientists to use data generated on analytical instruments like mass spectrometers to quickly identify and report protein sequences as well as any variations from the expected form. We innovate so that biopharmaceutical companies and university research labs can achieve confident results from their analysis and reporting. With our customers, we are boldly advancing protein characterization. Protein Metrics is headquartered in Cupertino, CA at the crossroads of computing and biotechnology in the San Francisco Bay Area. For more information, visit http://www.proteinmetrics.com. Media Contact:
SOURCE Intabio, Inc. |
View original content to download multimedia:
